Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H.

J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697.

PMID:
20151839
2.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
3.

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.

Cooper DA, Heera J, Ive P, Botes M, Dejesus E, Burnside R, Clumeck N, Walmsley S, Lazzarin A, Mukwaya G, Saag M, van Der Ryst E.

AIDS. 2014 Mar 13;28(5):717-25. doi: 10.1097/QAD.0000000000000131.

4.

Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.

Sierra-Madero J, Di Perri G, Wood R, Saag M, Frank I, Craig C, Burnside R, McCracken J, Pontani D, Goodrich J, Heera J, Mayer H.

HIV Clin Trials. 2010 May-Jun;11(3):125-32. doi: 10.1310/hct1103-125.

PMID:
20736149
5.

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Perry CM.

Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000. Review.

PMID:
20518583
6.

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

Lieberman-Blum SS, Fung HB, Bandres JC.

Clin Ther. 2008 Jul;30(7):1228-50. Review.

PMID:
18691983
7.

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.

J Infect Dis. 2008 Oct 15;198(8):1113-22. doi: 10.1086/592052.

8.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493.

PMID:
21890778
9.

[Maraviroc efficacy in clinical studies on the development of the molecule].

Moreno S, Hernández B, Gutiérrez C, Delsol E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:17-22. Review. Spanish.

PMID:
19133217
10.

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ; EPV20001 International Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):411-8. Epub 2004 Jul 15.

PMID:
15307010
11.

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H; A4001029 Study Group.

J Infect Dis. 2009 Jun 1;199(11):1638-47. doi: 10.1086/598965.

PMID:
19432546
12.

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team.

Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Erratum in: Clin Infect Dis. 2008 Dec 15;47(12):1611.

PMID:
18781872
13.

CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.

Bredeek UF, Harbour MJ.

Eur J Med Res. 2007 Oct 15;12(9):427-34. Review.

PMID:
17933724
14.

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC.

Int J Infect Dis. 2013 Oct;17(10):e875-82. doi: 10.1016/j.ijid.2013.02.020. Epub 2013 Apr 15.

15.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group.

N Engl J Med. 2006 Jan 19;354(3):251-60.

16.

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.

Yost R, Pasquale TR, Sahloff EG.

Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26. doi: 10.2146/ajhp080206. Review.

PMID:
19336831
17.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

18.

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M.

J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9.

PMID:
15247553
19.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
20.

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.

Hernández-Novoa B, Madrid-Elena N, Dronda F, Pérez-Elias MJ, Casado JL, Pérez-Molina JA, Moreno A, Estébanez M, González J, Zamora J, Moreno S.

J Antimicrob Chemother. 2014 Jul;69(7):1916-9. doi: 10.1093/jac/dku059. Epub 2014 Mar 12.

PMID:
24623833

Supplemental Content

Support Center